The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents.The disclosure also provides related compositions and methods of use.本發明提供使用HSP90抑制劑MPC-0767作為單藥療法及與其他活性劑呈組合療法治療包括但不限於造血癌及肺癌之癌症的方法，該等其他活性劑包括但不限於Bcl-2之抑制劑、EZH2抑制劑、Ras/Raf/MEK/ERK路徑抑制劑、檢查點抑制劑、DNMT抑制劑、ATO及化學治療劑。本發明亦提供相關組成物及使用方法。
